Gary S. Stetz, Chief Financial Officer and Director of Hepion Pharmaceuticals, Inc. (OTC:HEPA), filed a statement of changes in beneficial ownership on October 27, 2026, reporting the acquisition of stock options dated October 23, 2026.

Key Highlights

  • Reporting person: Gary S. Stetz, serving as both Chief Financial Officer and Director of Hepion Pharmaceuticals, Inc.
  • Options granted: 1,530,000 stock options acquired on October 23, 2026, with an exercise price of $0.14 per share.
  • Vesting schedule: 127,500 options vest in equal monthly amounts over 12 months from the date of grant, per the filing's explanation of responses.
  • Expiration date: The options expire on October 23, 2036, representing a 10-year term from grant date.
  • Price paid: The price of the derivative security is listed as $0, according to the filing.
  • Post-transaction holdings: Stetz beneficially owns 2,875,500 derivative securities following the reported transaction.

Hepion Pharmaceuticals CFO Stetz Receives Options Expiring in 2036

According to the filing, Gary S. Stetz, who holds dual roles as Chief Financial Officer and Director at Hepion Pharmaceuticals, Inc., was granted 1,530,000 stock options on October 23, 2026. The options carry an exercise price of $0.14 and are exercisable into an equivalent number of shares of common stock. The filing records the price of the derivative security as $0, and the options are set to expire on October 23, 2036.

Hepion Pharmaceuticals, Inc. trades on the OTC market under the ticker HEPA. The filing notes that 127,500 options vest in equal amounts monthly over 12 months from the date of grant, meaning the full grant vests over the course of one year on a monthly pro-rata basis. Following the reported transaction, Stetz beneficially owns 2,875,500 derivative securities in direct form, as disclosed in Table II of the filing.

The transaction was filed individually by Stetz as a single reporting person, with his address listed as c/o Hepion Pharmaceuticals, Inc., 22 West St., Suite 1B, Red Bank, New Jersey 07701. The filing was signed by Gary S. Stetz and dated October 27, 2026.

What Was Disclosed

The filing reported the acquisition of 1,530,000 stock options at an exercise price of $0.14 by Gary S. Stetz, CFO and Director of Hepion Pharmaceuticals, Inc. (OTC:HEPA), with the options expiring October 23, 2036, and post-transaction beneficial ownership of 2,875,500 derivative securities.